Erwan Bezard

Université de Bordeaux, Talence, Nouvelle-Aquitaine, France 
neurodegenerative disorders
"Erwan Bezard"

Bezard has authored or co-authored over 90 professional publications in the field of neurobiology, most of which are on Parkinson's disease and related disorders. He is perhaps best known for the reappraisal of both the identification of the nature of compensatory mechanisms that mask the progression Parkinson's disease and their sequential activation in non-human primate models that mimic Parkinson’s progression. His current research interests include the study of the compensatory mechanisms, the levodopa-induced dyskinesia, the basic pathophysiology of basal ganglia circuitry, and the development of new strategies to alleviate symptoms and/or to slow disease progression.

He has recently been appointed as a Visiting Professor at the China Academy of Medical Sciences (Beijing, China) where he has set-up and manages a non-human primate facility dedicated to Movement Disorders. He serves on the board of international organizations such as the International Basal Ganglia Society and the Michael J. Fox Foundation. He is Associate Editor of Neurobiology of Disease and he serves on the editorial boards of several neurobiology journals. Besides consulting for several drug companies in the field of movement disorders, he is a non-executive director of Plenitudes Sarl (France), Motac Neuroscience (UK) and Motac Cognition (USA).

(Show less)

Mean distance: 15.8 (cluster 6)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Ribot B, Aupy J, Vidailhet M, et al. (2020) Corrigendum to "Dystonia and dopamine: From phenomenology to pathophysiology" [Prog. Neurobiol. 182 (November) (2019), 101678, 18]. Progress in Neurobiology. 101745
Hulme H, Fridjonsdottir E, Gunnarsdottir H, et al. (2020) Simultaneous mass spectrometry imaging of multiple neuropeptides in the brain and alterations induced by experimental parkinsonism and L-DOPA therapy. Neurobiology of Disease. 104738
Bertin E, Deluc T, Pilch KS, et al. (2020) Increased surface P2X4 receptor regulates anxiety and memory in P2X4 internalization-defective knock-in mice. Molecular Psychiatry
Meissner WG, Fernagut PO, Dehay B, et al. (2019) Multiple System Atrophy: Recent Developments and Future Perspectives. Movement Disorders : Official Journal of the Movement Disorder Society
Dehay B, Bezard E. (2019) Intrastriatal injection of alpha-synuclein fibrils induces Parkinson-like pathology in macaques. Brain : a Journal of Neurology. 142: 3321-3322
Mercatelli D, Bezard E, Eleopra R, et al. (2019) Managing Parkinson's disease: Moving ON with NOP. British Journal of Pharmacology
Shariatgorji M, Nilsson A, Fridjonsdottir E, et al. (2019) Comprehensive mapping of neurotransmitter networks by MALDI-MS imaging. Nature Methods
Arotcarena ML, Bourdenx M, Dutheil N, et al. (2019) Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies. Jci Insight. 4
Ribot B, Aupy J, Vidailhet M, et al. (2019) Dystonia and dopamine: From phenomenology to pathophysiology. Progress in Neurobiology. 101678
Rosenblad C, Li Q, Pioli EY, et al. (2019) Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson's disease. Brain : a Journal of Neurology
See more...